{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T14:38:59Z","timestamp":1781275139808,"version":"3.54.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clml.2025.08.003","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T23:37:37Z","timestamp":1754437057000},"page":"e1077-e1085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pomalidomide, Cyclophosphamide, and Dexamethasone for Relapsed\/Refractory Multiple Myeloma: A Single-Center Experience"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9783","authenticated-orcid":false,"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Malandrakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8971-269X","authenticated-orcid":false,"given":"Charalampos","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9673-2624","authenticated-orcid":false,"given":"Sotirios","family":"Maganas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0618-8900","authenticated-orcid":false,"given":"Despina","family":"Fotiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6926-0351","authenticated-orcid":false,"given":"Foteini","family":"Theodorakakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Spiliopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Kanellias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalini","family":"Migkou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Eleutherakis-Papaiakovou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-1229","authenticated-orcid":false,"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2025.08.003_bib0001","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.08.003_bib0002","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.70012","article-title":"Determinants of 15-year progression-free survival in multiple myeloma; real-world data from a single institution","author":"Dimopoulos","year":"2025","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.clml.2025.08.003_bib0003","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2025.08.003_bib0004","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2025.08.003_bib0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","article-title":"Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.clml.2025.08.003_bib0006","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.clml.2025.08.003_bib0007","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"MAIA trial investigators. daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.clml.2025.08.003_bib0008","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"PERSEUS trial investigators. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.clml.2025.08.003_bib0009","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"IMROZ study group. Isatuximab, Bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2025.08.003_bib0010","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/s41375-019-0561-2","article-title":"Relapsed refractory multiple myeloma: a comprehensive overview","volume":"33","author":"Bazarbachi","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2025.08.003_bib0011","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/jha2.743","article-title":"Difficult-to-treat patients with relapsed\/refractory multiple myeloma: a review of clinical trial results","volume":"4","author":"Raab","year":"2023","journal-title":"EJHaem"},{"issue":"3","key":"10.1016\/j.clml.2025.08.003_bib0012","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1182\/blood-2009-05-221077","article-title":"Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia","volume":"115","author":"Pal","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.08.003_bib0013","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1182\/blood-2011-04-348896","article-title":"Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease","volume":"118","author":"Lacy","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.08.003_bib0014","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3390\/jcm10071509","article-title":"Pomalidomide plus low-dose dexamethasone in relapsed\/refractory multiple myeloma patients: results of the real-world \"POWERFUL\" study","volume":"10","author":"Terpos","year":"2021","journal-title":"J Clin Med"},{"issue":"23","key":"10.1016\/j.clml.2025.08.003_bib0015","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/bloodadvances.2019000539","article-title":"Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide\/dexamethasone","volume":"3","author":"Kastritis","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2025.08.003_bib0016","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjh.18772","article-title":"Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma","volume":"201","author":"Garderet","year":"2023","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.clml.2025.08.003_bib0017","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3390\/jcm8101695","article-title":"Clinical benefit of long-term disease control with pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma patients","volume":"8","author":"Parisi","year":"2019","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.clml.2025.08.003_bib0018","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.08.003_bib0019","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Trudel S; DREAMM-8 investigators. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med."},{"issue":"7","key":"10.1016\/j.clml.2025.08.003_bib0020","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.clml.2019.04.003","article-title":"Pomalidomide-based regimens for treatment of relapsed and relapsed\/refractory multiple myeloma: systematic review and meta-analysis of phase 2 and 3 clinical trials","volume":"19","author":"Mushtaq","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.08.003_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-139019","article-title":"Phase 3 study of pomalidomide with cyclophosphamide and dexamethasone versus pomalidomide and dexamethasone in asian patients with relapsed\/refractory myeloma (RRMM) - Interim analysis of a trial by the Asian myeloma network (AMN)","volume":"136","author":"Chng","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.08.003_bib0022","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clml.2021.02.004","article-title":"San Miguel JF. Pomalidomide, cyclophosphamide, and dexamethasone for the treatment of relapsed\/refractory multiple myeloma: real-world analysis of the pethema-GEM experience","volume":"21","author":"Rodriguez-Otero","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.clml.2025.08.003_bib0023","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00277-019-03649-3","article-title":"Pomalidomide, cyclophosphamide, and dexamethasone for relapsed\/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study","volume":"98","author":"Trudel","year":"2019","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.08.003_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260113","article-title":"Cyclophosphamide addition to pomalidomide\/dexamethasone is not necessarily associated with universal benefits in RRMM","volume":"17","author":"Park","year":"2022","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.clml.2025.08.003_bib0025","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/jha2.774","article-title":"The real-world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies","volume":"4","author":"Szabo","year":"2023","journal-title":"EJHaem"},{"issue":"24","key":"10.1016\/j.clml.2025.08.003_bib0026","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1182\/blood-2018-07-863829","article-title":"Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma","volume":"132","author":"Garderet","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.08.003_bib0027","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ajh.25726","article-title":"Korean Multiple Myeloma Working Party (KMMWP). Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)","volume":"95","author":"Lee","year":"2020","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.clml.2025.08.003_bib0028","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-019-0245-1","article-title":"Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed\/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network","volume":"9","author":"Soekojo","year":"2019","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.clml.2025.08.003_bib0029","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1080\/10428194.2020.1805111","article-title":"A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed\/refractory multiple myeloma","volume":"61","author":"Van Oekelen","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"10.1016\/j.clml.2025.08.003_bib0030","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","article-title":"Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma","volume":"127","author":"Baz","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.08.003_bib0031","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-019-0206-8","article-title":"Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial","volume":"9","author":"Weisel","year":"2019","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.clml.2025.08.003_bib0032","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2025.08.003_bib0033","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/S2352-3026(21)00381-1","article-title":"OCEAN (OP-103) Investigators. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study","volume":"9","author":"Schjesvold","year":"2022","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.clml.2025.08.003_bib0034","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ajh.27206","article-title":"Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: final results of the phase 2 study DARIA","volume":"99","author":"Terpos","year":"2024","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.clml.2025.08.003_bib0035","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/ajh.27382","article-title":"Ixazomib plus daratumumab and dexamethasone: final analysis of a phase 2 study among patients with relapsed\/refractory multiple myeloma","volume":"99","author":"Delimpasi","year":"2024","journal-title":"Am J Hematol"},{"issue":"17","key":"10.1016\/j.clml.2025.08.003_bib0036","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"TOURMALINE-MM1 Study Group. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2025.08.003_bib0037","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00277-020-03981-z","article-title":"Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed\/refractory multiple myeloma","volume":"99","author":"Terpos","year":"2020","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.clml.2025.08.003_bib0038","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.08.003_bib0039","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Trudel S; DREAMM-8 investigators. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.clml.2025.08.003_bib0040","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"DREAMM-7 investigators. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.08.003_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(25)00330-4","article-title":"DREAMM-7 study investigators. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial","author":"Hungria","year":"2025","journal-title":"Lancet Oncol"},{"issue":"10301","key":"10.1016\/j.clml.2025.08.003_bib0042","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.clml.2025.08.003_bib0043","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.clml.2025.08.003_bib0044","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T01:10:59Z","timestamp":1763773859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2152265025002666"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.08.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pomalidomide, Cyclophosphamide, and Dexamethasone for Relapsed\/Refractory Multiple Myeloma: A Single-Center Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}